

References

- ADDIN ZOTERO_BIBL {"uncited": [], "omitted": [], "custom": []} CSL_BIBLIOGRAPHY [1] 'Diabetes'. <https://www.who.int/news-room/fact-sheets/detail/diabetes> (accessed Oct. 16, 2020).
- [2] American Diabetes Association, 'Diagnosis and Classification of Diabetes Mellitus', *Diabetes Care*, vol. 32, no. Supplement_1, pp. S62–S67, Jan. 2009, doi: 10.2337/dc09-S062.
- [3] 'CDC Global Health - Indonesia', May 21, 2020. <https://www.cdc.gov/globalhealth/countries/indonesia/default.htm> (accessed Nov. 22, 2020).
- [4] T. Ligita, K. Wicking, K. Francis, N. Harvey, and I. Nurjannah, 'How people living with diabetes in Indonesia learn about their disease: A grounded theory study', *PLoS ONE*, vol. 14, no. 2, p. e0212019, Feb. 2019, doi: 10.1371/journal.pone.0212019.
- [5] J. B. Buse *et al.*, 'How Do We Define Cure of Diabetes?', *Diabetes Care*, vol. 32, no. 11, pp. 2133–2135, Nov. 2009, doi: 10.2337/dc09-9036.
- [6] 'Diabetes Mellitus Treatment', *ucsfhealth.org*. <https://www.ucsfhealth.org/conditions/diabetes-mellitus/treatment> (accessed Oct. 16, 2020).
- [7] 'Type 2 diabetes - Diagnosis and treatment - Mayo Clinic'. <https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199> (accessed Nov. 09, 2020).
- [8] Z.-Y. Zhang and S.-Y. Lee, 'PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity', *Expert Opin. Investig. Drugs*, p. 11, 2003.
- [9] H. Cho, 'Protein Tyrosine Phosphatase 1B (PTP1B) and Obesity', in *Vitamins & Hormones*, vol. 91, Elsevier, 2013, pp. 405–424. doi: 10.1016/B978-0-12-407766-9.00017-1.
- [10] N. Prakash and P. Devangi, 'Drug Discovery', *JAA*, vol. 02, no. 04, 2010, doi: 10.4172/jaa.1000025.
- [11] X. J. Yao *et al.*, 'Comparative Study of QSAR/QSPR Correlations Using Support Vector Machines, Radial Basis Function Neural Networks, and Multiple Linear Regression', *J. Chem. Inf. Comput. Sci.*, vol. 44, no. 4, pp. 1257–1266, Jul. 2004, doi: 10.1021/ci049965i.
- [12] I. Kurniawan, D. Tarwidi, and Jondri, 'QSAR modeling of PTP1B inhibitor by using Genetic algorithm-Neural network methods', *J. Phys.: Conf. Ser.*, vol. 1192, p. 012059, Mar. 2019, doi: 10.1088/1742-6596/1192/1/012059.
- [13] J. C. Patra and O. Singh, 'Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus', *J. Comput. Chem.*, vol. 30, no. 15, pp. 2494–2508, Nov. 2009, doi: 10.1002/jcc.21240.
- [14] D. Sokolović *et al.*, 'QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method', *Med Chem Res*, vol. 26, no. 4, pp. 796–804, Apr. 2017, doi: 10.1007/s00044-017-1792-2.
- [15] Y.-Y. Liu, X.-Y. Feng, W.-Q. Jia, Z. Jing, W.-R. Xu, and X.-C. Cheng, 'Virtual identification of novel PPAR α/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies', *Journal of Biomolecular Structure and Dynamics*, vol. 38, no. 9, pp. 2672–2685, Jun. 2020, doi: 10.1080/07391102.2019.1656110.
- [16] C. Nantasenamat, T. Monnor, A. Worachartcheewan, P. Mandi, C. Isarankura-Na-Ayudhya, and V. Prachayasittikul, 'Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection', *European Journal of Medicinal Chemistry*, vol. 76, pp. 352–359, Apr. 2014, doi: 10.1016/j.ejmech.2014.02.043.
- [17] E. H. L. Aarts and P. J. M. van Laarhoven, 'Simulated annealing: An introduction', *Statistica Neerlandica*, vol. 43, no. 1, pp. 31–52, 1989, doi: <https://doi.org/10.1111/j.1467-9574.1989.tb01245.x>.
- [18] S. Kirkpatrick, 'Optimization by simulated annealing: Quantitative studies', *J Stat Phys*, vol. 34, no. 5, pp. 975–986, Mar. 1984, doi: 10.1007/BF01009452.
- [19] F. Liang, 'Optimization Techniques — Simulated Annealing', *Medium*, Apr. 21, 2020. <https://towardsdatascience.com/optimization-techniques-simulated-annealing-d6a4785a1de7> (accessed Jun. 23, 2021).
- [20] V. Kecman, 'Support Vector Machines – An Introduction', in *Support Vector Machines: Theory and Applications*, L. Wang, Ed. Berlin, Heidelberg: Springer, 2005, pp. 1–47. doi: 10.1007/10984697_1.
- [21] 'ChEMBL Database'. <https://www.ebi.ac.uk/chembl/> (accessed Jun. 23, 2021).
- [22] D. Powers, 'Evaluation: From Precision, Recall and F-Factor to ROC, Informedness, Markedness & Correlation', *Mach. Learn. Technol.*, vol. 2, Jan. 2008.
- [23] E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, 'Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach', *Biometrics*, vol. 44, no. 3, pp. 837–845, 1988, doi: 10.2307/2531595.